GlobeNewswire by notified

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA

Share
  • Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.

  • Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers1,2

  • Sandoz continues to build on leading generic and biosimilar oncology portfolio to increase patient access and contribute to sustainability of healthcare systems

Basel, December 20, 2021 — Sandoz, a global leader in generic and biosimilar medicines, today announced the submission of its Biologics License Application (BLA) for a proposed biosimilar trastuzumab (150 mg, for intravenous use) developed by EirGenix, Inc. to the US Food and Drug Administration (FDA).

Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers1. Sandoz is seeking approval for the same indications as the reference medicine, based on a comprehensive package that includes analytical, preclinical and clinical data.

“Approximately 15-20% of all breast cancer patients have tumors that are HER2- positive2 and, as these tumors tend to grow more quickly than HER2-negative tumors,3 getting treated swiftly can be live-saving,” said Florian Bieber, Global Head of Biopharmaceuticals Development, Sandoz. “Trastuzumab is standard of care so, if approved, we will introduce more competition aiming to broaden access to this important therapy and liberate healthcare resources that can be used to fund other innovative medicines in the US."

Breast cancer is the most commonly diagnosed cancer among women in the US and associated death rates are the second highest of all cancers. It is estimated that about 30% of newly diagnosed cancers in women will be breast cancers in 20214.

As part of the license agreement signed in April 2019, EirGenix, Inc. is responsible for development and manufacturing and Sandoz will have the right to commercialize the medicine upon approval in all markets excluding China and Taiwan.

Sandoz has been developing and providing oncology medicines for over 30 years. Today, it has well over 50 such medicines, including chemotherapeutics, biologics, hormones and supportive care treatments, for the treatment of a wide range of cancers. The collaboration with EirGenix will enable Sandoz to build on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to the sustainability of healthcare systems.

Disclaimer 
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

References

  1. US FDA. Herceptin® (trastuzumab). Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf [Last accessed October 2021].
  2. Kowalczyk L, Bartsch R, Singer CF, Farr A. Adverse events of trastuzumab emtansine (T-DM1) in the treatment of HER-2 positive breast cancer patients. Breast Cancer (Basel) 2017;12(6):401–408.
  3. Dean L. Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype. In: Pratt V, McLeod H, Rubinstein W, et al. (Eds). Medical Genetics Summaries [online]. 5 August 2015. Bethesda (MD): National Center for Biotechnology Information (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK310376/ [Last accessed: October 2021].
  4. Breastcancer.org. U.S. Breast Cancer Statistics. Available from: https://www.breastcancer.org/symptoms/understand_bc/statistics [Last accessed: October 2021].

# # #

Richard Jarvis
Novartis Global Communications
+41 79 584 23 26 (mobile) richard.jarvis@novartis.com



Allison Schneider
Sandoz US Communications
+1 609 619 9089 (mobile)
allison.schneider@sandoz.com



Chris Lewis
Sandoz Global Communications
+49 174 244 9501 (mobile)
chris.lewis@sandoz.com

Novartis Media Relations
E-mail: media.relations@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Isabella Zinck +41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

DNO Receives 10 Awards in Norway's APA Licensing Round18.1.2022 15:54:11 CET | Press release

Oslo, 18 January 2022 – DNO ASA, the Norwegian oil and gas operator, today announced that its wholly-owned subsidiary DNO Norge AS has been awarded participation in 10 exploration licenses, of which three are operatorships, under Norway's Awards in Predefined Areas (APA) 2021 licensing round. Of the 10 new licenses, six are in the North Sea and four in the Norwegian Sea. At yearend 2021, DNO held interests in 73 licenses offshore Norway, of which 17 were operated by the Company. The new awards under the APA 2021 licensing round include: PL 586 B: Neptune Energy Norge AS (operator), Suncor Energy Norge AS, Vår Energi AS, DNO Norge AS (7.5%) PL 923 B: Equinor Energy AS (operator), Petoro AS, Wellesley Petroleum AS, DNO Norge AS (20%) PL 969 B: A/S Norske Shell (operator), Spirit Energy Norway, DNO Norge AS (45%) PL 1007 B: DNO Norge AS (operator, 40%), OMV (Norge) AS, Equinor Energy AS, Spirit Energy Norway AS PL 1145: DNO Norge AS (operator, 60%), Aker BP ASA PL 1146: ConocoPhillips Ska

AGC Biologics Names Regina Choi-Rivera New General Manager of Boulder, Colorado Mammalian Production Facility18.1.2022 15:05:00 CET | Press release

Boulder, Colo., Jan. 18, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations. “We’re incredibly excited that Ms. Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery. “Her breadth of knowledge and proven leadership give me great confidence that she is the right leader for our team, as well as our customers.” Ms. Choi-Rivera brings more than 25 years of experience in the biotech industry to this role and joins AGC Biologics after working for Samsun

Solidium’s CEO to change18.1.2022 14:01:05 CET | Press release

Solidium’s CEO, Antti Mäkinen, will leave his position as the CEO of Solidium on 31st May 2022. Mäkinen, 60, has acted as CEO of the company since year 2017. “The past five years have been rewarding and I have had the opportunity to work with an excellent team and great portfolio companies. Solidium has an established position and a strong track in growing shareholder value”, says Mäkinen. Antti Mäkinen has acted as a Board Member and Chairman of the Shareholders’ Nomination Committee in many of Solidium’s portfolio companies. He is still nominated this Spring in the Annual General Meetings i.a. as the Chairman of the Board in Stora Enso and a Member of the Board in Metso Outotec. The Chairman of the Board of Solidium, Harri Sailas, would like to thank Mäkinen for his work both in charge of Solidium and as Solidium’s representative in the portfolio companies. “In Antti Mäkinen’s steering, Solidiums position has stabilized and the company has been more active both as an owner and in mak

Solidiums verkställande direktör avgår18.1.2022 14:01:05 CET | Pressemelding

Solidiums verkställande direktör Antti Mäkinen lämnar sin post som VD den 31 maj 2022. Mäkinen, 60, har verkat i företagets ledning från och med år 2017. ”De senaste fem åren har varit givande och jag har fått arbeta med ett utmärkt team och fina portföljbolag. Solidium har en stabil position och bevisad förmåga att öka innehavens ägarvärde”, säger Mäkinen. Antti Mäkinen har verkat i flera av Solidiums portföljbolag som styrelsemedlem och som ordförande i aktieägarnas nomineringskommitté. Han är fortfarande nominerad i vårens bolagsstämmor bland annat som styrelseordförande i Stora Enso och styrelsemedlem i Metso Outotec. Solidiums styrelseordförande Harri Sailas tackar Mäkinen för arbetet både inom Solidiums ledning och som representant i Solidiums portföljbolag. ”Under ledning av Antti Mäkinen har Solidiums position etablerat sig och företaget har aktiverat sig både som ägare och vid att göra nya placeringar. Hans agerande har väckt uppskattning i alla företagets intressegrupper”, sä

RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.1.2022 11:30:00 CET | Press release

AuctionAuction resultsAuction date2022-01-18Maturity2024Tendered volume, SEK mln750 +/- 750Offered volume, SEK mln1593Volume bought, SEK mln1500Number of bids19Number of accepted bids19 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln720205600Volume bought, SEK mln627205600Number of bids4310Number of accepted bids4310Average DM-0.166-0.139-0.129-Lowest accepted DM-0.179-0.160-0.129-Highest DM-0.129-0.139-0.129-Accepted at lowest DM0.814100.00100.00- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln4081001000Volume bought, SEK mln4081001000Number of bids7310Number of accepted bids7310Average DM-0.133-0.129-0.140-Lowest accepted DM-0.160-0.129-0.140-Highest DM-0.120-0.129-0.140-Accepted at lowest DM100.00100.00100.00-

Aspo subsidiary ESL Shipping continues fleet renewal in accordance with its strategy by selling the barge Espa18.1.2022 11:15:00 CET | Press release

Aspo Plc Press Release January 18, 2022, at 12.15 p.m. Aspo subsidiary ESL Shipping continues fleetrenewal in accordance with its strategy by selling the barge Espa Aspo’s ESL Shipping continues fleet renewal by selling its smallest, 9000 dwt towable barge Espa to Raduga Shipping and Trading OÜ. The transaction was concluded and Espa subsequently delivered to her new owner today 18th of January. A sales gain of approximately 1.4 million euros will be recorded in the profit of ESL Shipping’s first quarter. Espa was built in 1987 as the last vessel of the Vuosaari shipyard in Helsinki. She was designed and equipped for efficient transportation and lightering of energy coal cargoes to powerplants in Helsinki. In recent years she was mainly used for cement industry transport demand. She also spent one summer as a floating beach volley field in Helsinki. Peculiarities in Finnish shipping policy led to increasing cost of barge towing tugboats, as tugboat crew could not receive state support